EUCTR2019-003114-13-DE进行中（未招募）1 期
Paclitaxel plus cetuximab for the treatment of recurrentand/or metastatic head and neck cancer after first-line checkpointinhibitor failure: A multicenter, single arm study - PACE ACE
Med. Univ. Wien, Klinik f. Innere Med. I, Onkologie0 个研究点目标入组 50 人开始时间: 2021年9月22日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- The patient has provided written informed consent prior to any study-related procedure.
- •· The patient is at least 18 years of age
- •- Histologically proven locally advanced unresectable, recurrent and/or metastatic squamous cell carcinoma of the oropharynx, hypopharynx, larynx or oral cavity not amenable for salvage surgery
- •· p16 status has to be determined for oropharyngeal carcinomas
- •· Documented progressive disease based on investigator assessment according to RECIST 1.1, following receipt of a pembrolizumab based regimen given as first line therapy in the platinum sensitive setting (i.e. = 6 months since last platinum exposure) for recurrent and/or metastatic SCCHN
- •· Measurable disease according to RECIST 1.1.
- •· The patient has a life expectancy of at least 3 months.
- •· Has a performance status of 0, 1 or 2 on the ECOG Performance Scale
- •· Female patient of childbearing potential should have a negative Urine or serum pregnancy 24 hours prior to treatment initiation If the Urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
- •· Female patients of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study until 120 days after the last dose of study medication. Patients of childbearing potential
- •are those who have not been surgically sterilized or have not been free from menses for > 1 year.
- •· Male patients should agree to use an adequate method of contraception starting with the first dose of study therapy until 120 days after the last dose of study therapy.
- •· Demonstrate adequate organ function as defined in table 1, all screening labs should be performed within 14 days of Treatment Initiation.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •- Prior taxane therapy is not allowed except as part of induction therapy for locally advanced disease (completed at least 6 months before study entry)
- •· Prior cetuximab therapy is not allowed except as part of either induction therapy or in combination with radiotherapy treatment for locally advanced disease (completed at least 6 months before study entry)
- •· Patients with nasopharyngeal carcinomas or salivary glands cancers
- •· Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy within 4 weeks of the first dose of treatment.
- •· Has a diagnosis of immunodeficiency including a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
- •· Has known active Hepatitis A/B or Hepatitis C
- •· Has had prior pembrolizumab within 1 week prior to study day 1 or who has not recovered (i.e., recovery to = Grade 1 or baseline grade prior to pembrolizumab) from (immune- related) adverse events other
- •than endocrine side effects.
- •· Has had prior chemotherapy or radiation therapy within 2 weeks Prior to study day 1 or who has not recovered (i.e., recovery to = Grade 1 or baseline grade prior to pembrolizumab) from adverse events due to a previously administered agent.
- •· Has had chemotherapy, targeted therapy or investigational drugs after checkpoint inhibitor failure for second line therapy.
- •- Has had prior pembrolizumab in the platinum resistant setting (<6 months after last platinum exposure).
- •· Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the Skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.
- •· Has an active infection requiring systemic therapy.
- •· Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient’s participation for the full duration of the
- •trial, or is not in the best interest of the patient to participate, in the opinion of the treating investigator.
- •· Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
- •· Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit until 120 days after the last dose of trial treatment
研究者
相似试验
进行中（未招募）
1 期
Paclitaxel plus cetuximab for the treatment of recurrentand/or metastatic head and neck cancer after first-line checkpointinhibitor failure: A multicenter, single arm studyEUCTR2019-003114-13-ATMed. Univ. Wien, Klinik f. Innere Med. I, Onkologie50
招募中
2 期
Paclitaxel with biweekly cetuximab for platinum- and immune checkpoint inhibitor-refractory head and neck cancerJPRN-jRCTs051200040Kiyota Naomi35
进行中（未招募）
不适用
Cetuximab and Cisplatin with or without Paclitaxel in recurrent/metastatic head and neck cancerRecurrent/metastatic head and neck squamous cell carcinomaMedDRA version: 14.1Level: LLTClassification code 10060121Term: Squamous cell carcinoma of head and neckSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-002564-24-ITISTITUTO NAZIONALE PER LA CURA TUMORI
已完成
2 期
Combination of Gemcitabine and Paclitaxel for urothelial carcinomarothelial carcionomaJPRN-UMIN000008357Saiseikai Yokohamashi Tobu Hospital40
进行中（未招募）
1 期
Cilengitide and Cetuximab in Combination With Platinum-basedChemotherapy as First-line Treatment for Subjects With Advanced NonSmall Cell Lung Cancer (NSCLC) (CERTO)EUCTR2008-004148-35-BEMerck KGaA215